Pub Date : 2018-09-05DOI: 10.33552/APPR.2018.01.000509
Sidaoui Abouamama, K. Noureddine, B. Anis, Terbeche Ryme, E. Younes, C. Mostafa, K. Mebrouk
The 20 isolates of Fusarium oxysporum f. sp. albedinis (Foa) produce amylase and cellulase enzymes, with the development of lysis zones around the inoculum (clear region) on the selective medium, indicates starch hydrolysis and cellulose degradation, with a variation in the ability of the isolates to produce these two enzymes, and this after measuring the diameters of the lysis zone. After Principal Component Analysis (PCA), we found that there is a strong positive correlation between mortality rate and amylolytic activity CP1 (74.80%) on the one hand and a weak correlation with cellulase CP2 (22.3%), on the other hand. While, there is no correlation between the pathogenicity of the isolates and the geographical origin of the isolate or cultivar from which this isolate was isolated P=0.3042.
20株尖孢镰刀菌(Fusarium oxysporum f. sp. albedinis, Foa)产生淀粉酶和纤维素酶,在选择性培养基上接种物周围(透明区域)形成裂解区,表明淀粉水解和纤维素降解,分离物产生这两种酶的能力有所不同,这是在测量裂解区直径后得出的结果。经主成分分析(PCA)发现,病死率与淀粉酶活性CP1(74.80%)呈正相关,与纤维素酶CP2(22.3%)呈弱相关。而分离株的致病性与分离株或栽培株的地理来源之间没有相关性(P=0.3042)。
{"title":"Correlation between Hydrolytic Enzymes Activity, Geographical Origin and Pathogenicity of Some Isolates of Fusarium oxysporum f. sp. albedinis","authors":"Sidaoui Abouamama, K. Noureddine, B. Anis, Terbeche Ryme, E. Younes, C. Mostafa, K. Mebrouk","doi":"10.33552/APPR.2018.01.000509","DOIUrl":"https://doi.org/10.33552/APPR.2018.01.000509","url":null,"abstract":"The 20 isolates of Fusarium oxysporum f. sp. albedinis (Foa) produce amylase and cellulase enzymes, with the development of lysis zones around the inoculum (clear region) on the selective medium, indicates starch hydrolysis and cellulose degradation, with a variation in the ability of the isolates to produce these two enzymes, and this after measuring the diameters of the lysis zone. After Principal Component Analysis (PCA), we found that there is a strong positive correlation between mortality rate and amylolytic activity CP1 (74.80%) on the one hand and a weak correlation with cellulase CP2 (22.3%), on the other hand. While, there is no correlation between the pathogenicity of the isolates and the geographical origin of the isolate or cultivar from which this isolate was isolated P=0.3042.","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"6 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84083201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-04DOI: 10.33552/APPR.2018.01.000508
Sidra Shafique
Underlying mechanisms of carcinogenic aberrations in genome stems from genetic mutations and epigenetic modulations followed by a cascade of mechanistic events in signaling pathways. Acetylation status have been identified as one of the key markers of cancerous cells along with the over expression of Histone deacetylases (HDACs). In this context, HDACs are the focus of cancer research both from the cause and the treatment perspectives. HDAC inhibitors are one of the time-tested therapeutics and have recently been used as an effective adjuvant with the combination therapeutic regimens of cancers such as breast cancer. Here, we discuss the HDAC inhibitors as cancer treatment option in context with carcinogenic role of epigenetic modifications. This work is licensed under Creative Commons Attribution 4.0 License APPR.MS.ID.000508. Archives of Pharmacy & Pharmacology Research Volume 1-Issue 2 Citation: Sidra Shafique. HDAC Inhibitors as Anticancer Therapeutics. Arch Phar & Pharmacol Res. 1(2): 2018. APPR.MS.ID.000508. DOI: 10.33552/APPR.2018.01.000508. Page 2 of 3 progenitor-like cells and differentiated tumor cells. The two popular proposed models of Hierarchic CSC and Dynamic CSC models may largely determine the therapeutic response to cancer treatment and recurrence that in turn is largely directed by the epigenetic coding of these cells. Breast cancer studies have been proto-type to study the cancer stem cell identification, such as CD44+/CD24–, ALDH+ circulating stem cells phenotype play an important role in breast cancer metastasis [6]. Another example of epigenetic role in CSC is depressed immune response by immune system. Immune response to cancer cells by T cells occurs through the antigen processing genes (TAP). Epigenetic dysregulations in cancer stem cells have been shown by the downregulated expression of TAP genes due to DNA hypermethylation indicating the epigenetic modifications being a candidate niche for therapeutic targets and drug development [7]. HDACi as Prospective Cancer Therapeutics HDACs are shown to be over-expressed in various human tumors. HDAC I, II and III in gastric, breast and colorectal cancer. Therefore, HDACs have been studied as biomarkers of tumors to identify the normal tissue and also as the prognostic indicators such as prostate cancer [8]. HDACs are over-expressed in cancer cells and are considered to play a key role in cancer cells survival. HDAC 1, 2, 3 and 6 knock down induce cell cycle arrest and apoptosis in lung, breast and colon carcinomas thus advocating HDACi as promising cancer therapeutics [2]. HDAC classes include I, II, III and IV. HDACs in class III have NAD-dependent catalytic sites and have the overlapping functions with classical HDACs [2]. (West & Johnstone, 2014). HDAC downregulation and inhibition by small molecules such as SAHA, TSA and Valproic acid produce hyperacetylation of genome, for example HDAC3 deletion results in increased H3K9, K14ac; H4K5ac; and H4K12ac [9,10]. HDACi results i
{"title":"HDAC Inhibitors as Anticancer Therapeutics","authors":"Sidra Shafique","doi":"10.33552/APPR.2018.01.000508","DOIUrl":"https://doi.org/10.33552/APPR.2018.01.000508","url":null,"abstract":"Underlying mechanisms of carcinogenic aberrations in genome stems from genetic mutations and epigenetic modulations followed by a cascade of mechanistic events in signaling pathways. Acetylation status have been identified as one of the key markers of cancerous cells along with the over expression of Histone deacetylases (HDACs). In this context, HDACs are the focus of cancer research both from the cause and the treatment perspectives. HDAC inhibitors are one of the time-tested therapeutics and have recently been used as an effective adjuvant with the combination therapeutic regimens of cancers such as breast cancer. Here, we discuss the HDAC inhibitors as cancer treatment option in context with carcinogenic role of epigenetic modifications. This work is licensed under Creative Commons Attribution 4.0 License APPR.MS.ID.000508. Archives of Pharmacy & Pharmacology Research Volume 1-Issue 2 Citation: Sidra Shafique. HDAC Inhibitors as Anticancer Therapeutics. Arch Phar & Pharmacol Res. 1(2): 2018. APPR.MS.ID.000508. DOI: 10.33552/APPR.2018.01.000508. Page 2 of 3 progenitor-like cells and differentiated tumor cells. The two popular proposed models of Hierarchic CSC and Dynamic CSC models may largely determine the therapeutic response to cancer treatment and recurrence that in turn is largely directed by the epigenetic coding of these cells. Breast cancer studies have been proto-type to study the cancer stem cell identification, such as CD44+/CD24–, ALDH+ circulating stem cells phenotype play an important role in breast cancer metastasis [6]. Another example of epigenetic role in CSC is depressed immune response by immune system. Immune response to cancer cells by T cells occurs through the antigen processing genes (TAP). Epigenetic dysregulations in cancer stem cells have been shown by the downregulated expression of TAP genes due to DNA hypermethylation indicating the epigenetic modifications being a candidate niche for therapeutic targets and drug development [7]. HDACi as Prospective Cancer Therapeutics HDACs are shown to be over-expressed in various human tumors. HDAC I, II and III in gastric, breast and colorectal cancer. Therefore, HDACs have been studied as biomarkers of tumors to identify the normal tissue and also as the prognostic indicators such as prostate cancer [8]. HDACs are over-expressed in cancer cells and are considered to play a key role in cancer cells survival. HDAC 1, 2, 3 and 6 knock down induce cell cycle arrest and apoptosis in lung, breast and colon carcinomas thus advocating HDACi as promising cancer therapeutics [2]. HDAC classes include I, II, III and IV. HDACs in class III have NAD-dependent catalytic sites and have the overlapping functions with classical HDACs [2]. (West & Johnstone, 2014). HDAC downregulation and inhibition by small molecules such as SAHA, TSA and Valproic acid produce hyperacetylation of genome, for example HDAC3 deletion results in increased H3K9, K14ac; H4K5ac; and H4K12ac [9,10]. HDACi results i","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"27 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74130949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-09-01DOI: 10.33552/APPR.2018.01.000506
S. Gambo, M. Ali, S. U. Diso, N. S. Abubakar
Wound infections have been recognized as the most critical problem especially in the presence of foreign materials that increase the risk of serious infection even with relatively small bacterial infection. This study was carried out to determine the antibacterial activity of honey against clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa obtained from infected wounds. Different concentrations of honey extract (25, 50, 75 and 100 v/v) were tested using agar well diffusion method to determine their antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa isolated from infected wounds of patients attending Muhammad Abdullahi Wase Specialist Hospital, Kano. The antibacterial activity of the honey showed that the honey demonstrated antimicrobial activity against the test isolates with higher activity in Staphylococcus aureus (with average zone of inhibition of 15.90mm) than Pseudomonas aeruginosa (14.63mm). The minimum inhibitory concentration (MIC) of the extract from this study ranges from 6.25 – 50mg/ml while the minimum bactericidal concentration (MBC) of the extracts ranges from 25 – 50mg/ml. Statistical analysis of the results showed that there is no significant different in the activity of honey against the isolates at p<0.05. Based on the results of this study, it is concluded that honey is active against wound bacterial isolates and can be used as a therapy for wound infection.
{"title":"Antibacterial Activity of Honey Against Staphylococcus Aureus and Pseudomonas aeruginosa Isolated from Infected Wound","authors":"S. Gambo, M. Ali, S. U. Diso, N. S. Abubakar","doi":"10.33552/APPR.2018.01.000506","DOIUrl":"https://doi.org/10.33552/APPR.2018.01.000506","url":null,"abstract":"Wound infections have been recognized as the most critical problem especially in the presence of foreign materials that increase the risk of serious infection even with relatively small bacterial infection. This study was carried out to determine the antibacterial activity of honey against clinical isolates of Staphylococcus aureus and Pseudomonas aeruginosa obtained from infected wounds. Different concentrations of honey extract (25, 50, 75 and 100 v/v) were tested using agar well diffusion method to determine their antibacterial activity against Staphylococcus aureus and Pseudomonas aeruginosa isolated from infected wounds of patients attending Muhammad Abdullahi Wase Specialist Hospital, Kano. The antibacterial activity of the honey showed that the honey demonstrated antimicrobial activity against the test isolates with higher activity in Staphylococcus aureus (with average zone of inhibition of 15.90mm) than Pseudomonas aeruginosa (14.63mm). The minimum inhibitory concentration (MIC) of the extract from this study ranges from 6.25 – 50mg/ml while the minimum bactericidal concentration (MBC) of the extracts ranges from 25 – 50mg/ml. Statistical analysis of the results showed that there is no significant different in the activity of honey against the isolates at p<0.05. Based on the results of this study, it is concluded that honey is active against wound bacterial isolates and can be used as a therapy for wound infection.","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"os-2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87185191","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-26DOI: 10.33552/APPR.2018.01.000504
B. Mushtaq
{"title":"Role of Psychiatry Nurse in Anti-Manic Drugs","authors":"B. Mushtaq","doi":"10.33552/APPR.2018.01.000504","DOIUrl":"https://doi.org/10.33552/APPR.2018.01.000504","url":null,"abstract":"","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"87 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83804595","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-08-12DOI: 10.33552/APPR.2018.01.000503
Abduelmula R Abduelkarem, Enas Z Elkrewi, Israa N Shatat, Nesreen M Alsebai, Warda M Ismail
Objectives: The aim of this study was to investigate pharmacists’ perception and attitude towards OTC drug advertising in Abu Dhabi, UAE. Study design: A cross-sectional study. Methods: A pre-piloted 35-item questionnaire was distributed to 130 pharmacists, who were agreed to take part in the study from Abu Dhabi Health Authority, UAE. Results: The majority of respondents watched OTC advertisements on the internet (43.1%) and television (35.4%), at least 1-5 times per week. Half of the pharmacists (50.0%) reported that patients interacted with them more than 10 times per week about OTC drugs. Most of the participants (88.5%) thought that advertising makes them aware of new products in the market, and more than half of them (60.0%) admitted that it influences their decisions when patients seek advice. Conclusion: Pharmacists in Abu Dhabi, UAE seem to be less conservative about the subject of drug advertising regarding its impact on their practice. Nonetheless, they are fully aware that such advertisements could lead to undesirable consequences, such as misuse or abuse of OTC products, increased chances of potential adverse events and increased costs.
{"title":"Perception of Over the Counter Drug Advertising among Pharmacists in Abu Dhabi, UAE","authors":"Abduelmula R Abduelkarem, Enas Z Elkrewi, Israa N Shatat, Nesreen M Alsebai, Warda M Ismail","doi":"10.33552/APPR.2018.01.000503","DOIUrl":"https://doi.org/10.33552/APPR.2018.01.000503","url":null,"abstract":"Objectives: The aim of this study was to investigate pharmacists’ perception and attitude towards OTC drug advertising in Abu Dhabi, UAE. Study design: A cross-sectional study. Methods: A pre-piloted 35-item questionnaire was distributed to 130 pharmacists, who were agreed to take part in the study from Abu Dhabi Health Authority, UAE. Results: The majority of respondents watched OTC advertisements on the internet (43.1%) and television (35.4%), at least 1-5 times per week. Half of the pharmacists (50.0%) reported that patients interacted with them more than 10 times per week about OTC drugs. Most of the participants (88.5%) thought that advertising makes them aware of new products in the market, and more than half of them (60.0%) admitted that it influences their decisions when patients seek advice. Conclusion: Pharmacists in Abu Dhabi, UAE seem to be less conservative about the subject of drug advertising regarding its impact on their practice. Nonetheless, they are fully aware that such advertisements could lead to undesirable consequences, such as misuse or abuse of OTC products, increased chances of potential adverse events and increased costs.","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"54 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84591558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-07-20DOI: 10.33552/APPR.2018.01.000501
G. Kordas
We developed a quadrupole stimuli responsive targeted nanomedicine platform with the key goal to provide a solution to the outstanding problem “How can the delivered therapeutic dose to the tumour be increased while at the same time reducing the dose in healthy tissue?” When accomplishing this goal, we will offer a huge improvement in the length and quality of life of cancer patients. Our preliminary animal study give hope in that course. We attempted to accomplish this goal via an innovative and patented therapeutic approach based on novel polymeric nanocarriers (NCs), which enables targeted drug delivery in tumors. The in-vivo results suggest that both Nano4Dox and Nano4Cis platforms outperforms the commercial standards like Doxil® and Lipoplatin, respectively. These platforms offer a significant business opportunity besides the therapeutic value offering to millions of people hope for better life and cure. This work is licensed under Creative Commons Attribution 4.0 License APPR.MS.ID.000501. Archives of Pharmacy & Pharmacology Research Volume 1-Issue 1 Citation: George K. Adjustable Quarto Stimuli (T, pH, Redox, Hyperthermia) Targeted Nanocontainers (Nano4Dox and Nano4Cis) for Cancer Therapy Based on Trojan Horse Approach. Arch Phar & Pharmacol Res. 1(1): 2018. APPR.MS.ID.000501. Page 2 of 7 targeting pathological tissue, inducing localised drug release. This technology leverages the fact that tumors (as well as other types of diseased tissue) are known to have specific extracellular environments with lower pH, higher temperature and/ or enhanced glutathione levels compared to healthy tissues. Furthermore, the Nano4XX platforms are grafted with targeting groups e.g. folic acid for breast cancer, leuprolide for prostate cancer, etc. The Nano4XX platforms are designed such to become unstable specifically under the conditions present in cancer, the release of the encapsulated compounds is directed at the target tissue. As such, encapsulating drugs in our Nano4XX has a beneficial effect on the accumulating dose in target tissue and thus the intended effect of the drug as well as on unwanted side-effects on healthy tissues. The Nano4XX platforms integrate four stimuli, namely pH, temperature (T), reducing environments (glutathione) and alternating magnetic fields (Figure 1). Loading and release studies with anthracycline antibiotics confirm the high loading capacity of the NCs along with the sensitive response to any needed combination of stimuli. Figure 1: Principle of the Nano4XX platform. We have observed in vivo and in vitro evidence of the functional added value of our proprietary [20] Nano4XX for the delivery of anti-tumour and antibacterial drugs. Furthermore, we have a strong IP position and developed a business plan that describes the optimal route-to-market for our technology [21]. Just to mention the business opportunity of our system, the doxorubicin global market volume was USD 0.81 billion in 2015 and is expected to reach a value of
我们开发了一个四极刺激反应靶向纳米医学平台,其关键目标是为“如何在增加肿瘤治疗剂量的同时减少健康组织的剂量”这一突出问题提供解决方案?当实现这一目标时,我们将为癌症患者的生命长度和生活质量提供巨大的改善。我们初步的动物实验给了我们希望。我们试图通过一种基于新型聚合物纳米载体(NCs)的创新和专利治疗方法来实现这一目标,该方法可以在肿瘤中靶向给药。体内实验结果表明,Nano4Dox和Nano4Cis平台分别优于Doxil®和Lipoplatin等商业标准。这些平台除了提供治疗价值外,还为数百万人提供了改善生活和治愈的希望,提供了重要的商业机会。本作品采用知识共享署名4.0许可协议apprs . ms . id .000501。基于特洛伊木马方法的癌症治疗可调四开元刺激(T, pH,氧化还原,热疗)靶向纳米容器(Nano4Dox和Nano4Cis)。医药科学,2018(1):18 - 18。APPR.MS.ID.000501。Page of 7靶向病理组织,诱导局部药物释放。这项技术利用了这样一个事实,即肿瘤(以及其他类型的病变组织)已知具有与健康组织相比具有较低pH值,较高温度和谷胱甘肽水平增强的特定细胞外环境。此外,Nano4XX平台还移植了靶向组,例如针对乳腺癌的叶酸,针对前列腺癌的leuprolide等。Nano4XX平台被设计成在癌症存在的条件下变得不稳定,被封装的化合物的释放直接针对目标组织。因此,在我们的Nano4XX中封装药物对靶组织中的累积剂量有有益的影响,从而达到药物的预期效果,以及对健康组织的不良副作用。Nano4XX平台集成了四种刺激,即pH、温度(T)、还原环境(谷胱甘肽)和交变磁场(图1)。蒽环类抗生素的加载和释放研究证实了NCs的高负载能力以及对任何所需刺激组合的敏感反应。图1:Nano4XX平台的原理。我们已经在体内和体外观察到我们的专利[20]Nano4XX在抗肿瘤和抗菌药物输送方面的功能附加价值的证据。此外,我们拥有强大的知识产权地位,并制定了一项商业计划,描述了我们技术的最佳市场路线[21]。仅提一下我们系统的商机,根据Grand View Research, Inc.的一份新报告,2015年阿霉素全球市场规模为8.1亿美元,预计到2024年将达到13.8亿美元[22]。如果我们的系统通过临床试验,我们将首先为肿瘤提供安全的药物输送,其次是巨大的商业机会。因为我们可以在我们的Nano4XX平台上加载任何商业药物,我们的技术呈现出相应的商业潜力乘以每种药物的市场价值。癌症治疗的商业革命。
{"title":"Adjustable Quarto Stimuli (T, pH, Redox, Hyperthermia) Targeted Nanocontainers (Nano4Dox and Nano4Cis) for Cancer Therapy Based on Trojan Horse Approach","authors":"G. Kordas","doi":"10.33552/APPR.2018.01.000501","DOIUrl":"https://doi.org/10.33552/APPR.2018.01.000501","url":null,"abstract":"We developed a quadrupole stimuli responsive targeted nanomedicine platform with the key goal to provide a solution to the outstanding problem “How can the delivered therapeutic dose to the tumour be increased while at the same time reducing the dose in healthy tissue?” When accomplishing this goal, we will offer a huge improvement in the length and quality of life of cancer patients. Our preliminary animal study give hope in that course. We attempted to accomplish this goal via an innovative and patented therapeutic approach based on novel polymeric nanocarriers (NCs), which enables targeted drug delivery in tumors. The in-vivo results suggest that both Nano4Dox and Nano4Cis platforms outperforms the commercial standards like Doxil® and Lipoplatin, respectively. These platforms offer a significant business opportunity besides the therapeutic value offering to millions of people hope for better life and cure. This work is licensed under Creative Commons Attribution 4.0 License APPR.MS.ID.000501. Archives of Pharmacy & Pharmacology Research Volume 1-Issue 1 Citation: George K. Adjustable Quarto Stimuli (T, pH, Redox, Hyperthermia) Targeted Nanocontainers (Nano4Dox and Nano4Cis) for Cancer Therapy Based on Trojan Horse Approach. Arch Phar & Pharmacol Res. 1(1): 2018. APPR.MS.ID.000501. Page 2 of 7 targeting pathological tissue, inducing localised drug release. This technology leverages the fact that tumors (as well as other types of diseased tissue) are known to have specific extracellular environments with lower pH, higher temperature and/ or enhanced glutathione levels compared to healthy tissues. Furthermore, the Nano4XX platforms are grafted with targeting groups e.g. folic acid for breast cancer, leuprolide for prostate cancer, etc. The Nano4XX platforms are designed such to become unstable specifically under the conditions present in cancer, the release of the encapsulated compounds is directed at the target tissue. As such, encapsulating drugs in our Nano4XX has a beneficial effect on the accumulating dose in target tissue and thus the intended effect of the drug as well as on unwanted side-effects on healthy tissues. The Nano4XX platforms integrate four stimuli, namely pH, temperature (T), reducing environments (glutathione) and alternating magnetic fields (Figure 1). Loading and release studies with anthracycline antibiotics confirm the high loading capacity of the NCs along with the sensitive response to any needed combination of stimuli. Figure 1: Principle of the Nano4XX platform. We have observed in vivo and in vitro evidence of the functional added value of our proprietary [20] Nano4XX for the delivery of anti-tumour and antibacterial drugs. Furthermore, we have a strong IP position and developed a business plan that describes the optimal route-to-market for our technology [21]. Just to mention the business opportunity of our system, the doxorubicin global market volume was USD 0.81 billion in 2015 and is expected to reach a value of ","PeriodicalId":8291,"journal":{"name":"Archives of Pharmacy & Pharmacology Research","volume":"8 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-07-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81270383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}